LOCALLY ADVANCED URETHRAL UROTHELIAL CARCINOMA
Clinical trials for LOCALLY ADVANCED URETHRAL UROTHELIAL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new LOCALLY ADVANCED URETHRAL UROTHELIAL CARCINOMA trials appear
Sign up with your email to follow new studies for LOCALLY ADVANCED URETHRAL UROTHELIAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo targets tough bladder cancers
Disease control OngoingThis early-stage trial tests a combination of two drugs—erdafitinib and enfortumab vedotin—for people with advanced bladder cancer that has spread and has specific FGFR2/3 gene changes. The goal is to find the safest and most effective dose and see if the combo can shrink or stab…
Matched conditions: LOCALLY ADVANCED URETHRAL UROTHELIAL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 07:18 UTC
-
New hope for bladder cancer patients who Can't take standard chemo
Disease control OngoingThis study tests whether adding the chemotherapy drug eribulin to the immunotherapy atezolizumab works better than atezolizumab alone for people with advanced bladder cancer that has spread. The trial includes 72 adults whose cancer cannot be treated with the standard cisplatin c…
Matched conditions: LOCALLY ADVANCED URETHRAL UROTHELIAL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 07:17 UTC
-
Bladder cancer breakthrough? trial tests stopping immunotherapy early
Disease control OngoingThis study looks at whether people with advanced bladder cancer can stop taking immunotherapy drugs (like pembrolizumab or nivolumab) after about a year instead of continuing indefinitely. The goal is to see if stopping early leads to similar survival rates while reducing side ef…
Matched conditions: LOCALLY ADVANCED URETHRAL UROTHELIAL CARCINOMA
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated May 26, 2026 06:53 UTC
-
New combo aims to tame Immunotherapy's side effects in advanced cancers
Disease control OngoingThis study tests whether adding tocilizumab to standard immunotherapy (ipilimumab and nivolumab) can reduce severe side effects in people with advanced melanoma, lung cancer, or bladder cancer. About 35 participants will receive the combination to see if it is safer and still eff…
Matched conditions: LOCALLY ADVANCED URETHRAL UROTHELIAL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 20, 2026 11:57 UTC
-
Could a common heart pill boost cancer immunotherapy?
Disease control OngoingThis study tests adding propranolol, a blood pressure drug, to standard immunotherapy for people with advanced bladder cancer that has spread. The goal is to see if the combination is safe and helps control the cancer. Only 6 adults took part, and the study is no longer recruitin…
Matched conditions: LOCALLY ADVANCED URETHRAL UROTHELIAL CARCINOMA
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated May 08, 2026 12:03 UTC
-
Can your genes tell if immunotherapy will work? new study investigates
Knowledge-focused OngoingThis study looks at whether specific gene mutations (ARID1A and KDM6A) and a protein called CXCL13 can predict how well the immunotherapy drug nivolumab works in people with advanced bladder cancer that has spread. About 6 participants with these gene changes will receive nivolum…
Matched conditions: LOCALLY ADVANCED URETHRAL UROTHELIAL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated May 26, 2026 07:22 UTC